vs

Side-by-side financial comparison of OmniAb, Inc. (OABI) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.

TRANSACT TECHNOLOGIES INC is the larger business by last-quarter revenue ($11.5M vs $8.4M, roughly 1.4× OmniAb, Inc.). On growth, TRANSACT TECHNOLOGIES INC posted the faster year-over-year revenue change (11.9% vs -22.5%). TRANSACT TECHNOLOGIES INC produced more free cash flow last quarter ($589.0K vs $-5.7M). Over the past eight quarters, TRANSACT TECHNOLOGIES INC's revenue compounded faster (3.5% CAGR vs -51.3%).

OmniAb, Inc. is a global biotechnology firm specializing in proprietary transgenic animal platforms and antibody discovery solutions. It partners with pharma and biotech clients to accelerate fully human therapeutic antibody development for oncology, autoimmune diseases and high-need medical areas across key global markets.

Roper Technologies, Inc. is a holding company that owns companies in the technology sector.

OABI vs TACT — Head-to-Head

Bigger by revenue
TACT
TACT
1.4× larger
TACT
$11.5M
$8.4M
OABI
Growing faster (revenue YoY)
TACT
TACT
+34.4% gap
TACT
11.9%
-22.5%
OABI
More free cash flow
TACT
TACT
$6.3M more FCF
TACT
$589.0K
$-5.7M
OABI
Faster 2-yr revenue CAGR
TACT
TACT
Annualised
TACT
3.5%
-51.3%
OABI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
OABI
OABI
TACT
TACT
Revenue
$8.4M
$11.5M
Net Profit
$-14.2M
Gross Margin
47.6%
Operating Margin
-188.2%
-10.1%
Net Margin
-169.3%
Revenue YoY
-22.5%
11.9%
Net Profit YoY
-8.5%
EPS (diluted)
$-0.11
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OABI
OABI
TACT
TACT
Q4 25
$8.4M
$11.5M
Q3 25
$13.2M
Q2 25
$13.8M
Q1 25
$13.1M
Q4 24
$10.8M
$10.2M
Q3 24
$10.9M
Q2 24
$7.6M
$11.6M
Q1 24
$10.7M
Net Profit
OABI
OABI
TACT
TACT
Q4 25
$-14.2M
Q3 25
$15.0K
Q2 25
$-143.0K
Q1 25
$19.0K
Q4 24
$-13.1M
Q3 24
$-551.0K
Q2 24
$-13.6M
$-319.0K
Q1 24
$-1.0M
Gross Margin
OABI
OABI
TACT
TACT
Q4 25
47.6%
Q3 25
49.8%
Q2 25
48.2%
Q1 25
48.7%
Q4 24
44.2%
Q3 24
48.1%
Q2 24
52.7%
Q1 24
52.6%
Operating Margin
OABI
OABI
TACT
TACT
Q4 25
-188.2%
-10.1%
Q3 25
0.1%
Q2 25
-1.9%
Q1 25
-0.1%
Q4 24
-147.0%
-10.3%
Q3 24
-7.7%
Q2 24
-214.1%
-3.8%
Q1 24
-12.2%
Net Margin
OABI
OABI
TACT
TACT
Q4 25
-169.3%
Q3 25
0.1%
Q2 25
-1.0%
Q1 25
0.1%
Q4 24
-121.0%
Q3 24
-5.1%
Q2 24
-179.0%
-2.8%
Q1 24
-9.7%
EPS (diluted)
OABI
OABI
TACT
TACT
Q4 25
$-0.11
$-0.11
Q3 25
$0.00
Q2 25
$-0.01
Q1 25
$0.00
Q4 24
$-0.13
$-0.80
Q3 24
$-0.06
Q2 24
$-0.13
$-0.03
Q1 24
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OABI
OABI
TACT
TACT
Cash + ST InvestmentsLiquidity on hand
$25.5M
$20.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$267.0M
$31.1M
Total Assets
$300.9M
$44.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OABI
OABI
TACT
TACT
Q4 25
$25.5M
$20.4M
Q3 25
$20.0M
Q2 25
$17.7M
Q1 25
$14.2M
Q4 24
$27.6M
$14.4M
Q3 24
$11.3M
Q2 24
$20.8M
$11.1M
Q1 24
$10.6M
Stockholders' Equity
OABI
OABI
TACT
TACT
Q4 25
$267.0M
$31.1M
Q3 25
$31.8M
Q2 25
$31.3M
Q1 25
$30.9M
Q4 24
$287.6M
$30.6M
Q3 24
$38.4M
Q2 24
$294.2M
$38.5M
Q1 24
$38.6M
Total Assets
OABI
OABI
TACT
TACT
Q4 25
$300.9M
$44.8M
Q3 25
$45.0M
Q2 25
$44.5M
Q1 25
$44.2M
Q4 24
$325.6M
$44.0M
Q3 24
$50.5M
Q2 24
$337.3M
$50.4M
Q1 24
$51.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OABI
OABI
TACT
TACT
Operating Cash FlowLast quarter
$-5.7M
$609.0K
Free Cash FlowOCF − Capex
$-5.7M
$589.0K
FCF MarginFCF / Revenue
-67.8%
5.1%
Capex IntensityCapex / Revenue
0.1%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-31.8M
$7.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OABI
OABI
TACT
TACT
Q4 25
$-5.7M
$609.0K
Q3 25
$3.6M
Q2 25
$3.6M
Q1 25
$-161.0K
Q4 24
$-3.9M
$2.4M
Q3 24
$327.0K
Q2 24
$-12.2M
$636.0K
Q1 24
$-1.5M
Free Cash Flow
OABI
OABI
TACT
TACT
Q4 25
$-5.7M
$589.0K
Q3 25
$3.6M
Q2 25
$3.6M
Q1 25
$-171.0K
Q4 24
$-3.9M
$2.4M
Q3 24
$259.0K
Q2 24
$-12.9M
$499.0K
Q1 24
$-1.6M
FCF Margin
OABI
OABI
TACT
TACT
Q4 25
-67.8%
5.1%
Q3 25
27.1%
Q2 25
25.9%
Q1 25
-1.3%
Q4 24
-36.3%
23.2%
Q3 24
2.4%
Q2 24
-169.9%
4.3%
Q1 24
-14.9%
Capex Intensity
OABI
OABI
TACT
TACT
Q4 25
0.1%
0.2%
Q3 25
0.5%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.4%
0.1%
Q3 24
0.6%
Q2 24
9.9%
1.2%
Q1 24
1.0%
Cash Conversion
OABI
OABI
TACT
TACT
Q4 25
Q3 25
242.00×
Q2 25
Q1 25
-8.47×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons